| Source: |
| Type: |
| BCR‑ABL is a well‐characterized fusion oncoprotein resulting from a chromosomal translocation that has significant diagnostic, prognostic, and therapeutic relevance in hematologic malignancies. – It promotes uncontrolled cell proliferation, inhibits apoptosis, and contributes to genomic instability. – Quantitative measurement of BCR‑ABL transcript levels is used to monitor minimal residual disease (MRD) and predict response to therapy. – BCR‑ABL is not only a diagnostic hallmark of CML and certain ALL cases but also a critical driver of disease progression that can be effectively targeted by molecular therapies. |
| 1358- | Ash, | Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1075 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid